Overview

Study of Anti-PSMA CAR NK Cell (TABP EIC) in Metastatic Castration-Resistant Prostate Cancer

Status:
Recruiting

Trial end date:
2024-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety, tolerability and preliminary efficacy of TABP EIC in patients with Metastatic castration-resistant prostate cancer.

Phase:

Early Phase 1

Details

Lead Sponsor:

Allife Medical Science and Technology Co., Ltd.

Collaborator:

Tianjin People's Hospital

Treatments:

Cyclophosphamide
Fludarabine